Crystal form and amorphous form of carebastine p-toluenesulfonate
AssigneeChengdu Shibeikang Biomedical Technology Co., Ltd.
InventorsXiaoyu WANG, Li ZHANG, Jie JIANG, Ning ZHOU, Xia MOU
Life of this patent
Estimating the term…
Abstract
Provided are a crystal form and amorphous form of carebastine p-toluenesulfonate, and a preparation method therefor, relating to the field of medicinal chemistry, for use in solving the problems in the prior art that carebastine is unstable, not easy to scale up for synthesis, and difficult to make into a drug and the like. The crystal form and amorphous form of carebastine p-toluenesulfonate have the characteristics of high purity, high stability, high bioavailability, easy scale-up synthesis, and industrial production and the like, and have excellent hygroscopicity for easy storage.
Claims14
A crystal form of a compound represented by formula (1),
- wherein the crystal form has an X-ray powder diffraction pattern obtained by Cu-Kα radiation that has diffraction peaks at 2θ positions of:
- 4.26±0.2°, 6.43±0.2°, 14.49±0.2°, 15.11±0.2°, and 18.95±0.2°.
An amorphous form of a compound represented by formula (1),
- wherein the amorphous form has an X-ray powder diffraction pattern obtained by Cu-Kα radiation which is represented by a diffuse peak;
- preferably, the amorphous form has an X-ray powder diffraction pattern substantially as shown in FIG. 5.
Dependencies are inferred from the claim text.